论文部分内容阅读
非小细胞肺癌(NSCLC)为当今最常见的恶性肿瘤之一,近年来我国肺癌的发病率和病死率增长迅速,已居癌症相关死亡首位。分子靶向治疗已成为晚期NSCLC治疗的研究热点之一,靶向药物如何针对性地用于患者的治疗是关键。棘皮动物微管结合蛋白4(EML4)与间变淋巴瘤激酶(ALK)形成的融合基因主要表达于NSCLC中,这可能是与NSCLC表皮生长因子受体酪氨酸激酶抑制剂耐药相关的新靶点。
Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors in our country. In recent years, the incidence and mortality of lung cancer in our country have been increasing rapidly and have become the first cancer-related death. Molecular targeted therapy has become one of the hot topics in the treatment of advanced NSCLC, and it is the key to how the targeted drugs can be targetedly used in the treatment of patients. Echinoderm microtubule-associated protein 4 (EML4) and anaplastic lymphoma kinase (ALK) the formation of the fusion gene is mainly expressed in NSCLC, which may be associated with NSCLC epidermal growth factor receptor tyrosine kinase inhibitor drug-resistant new Targets.